Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26671816 | 0.75 | KDR (0.43) | — | |
| SCHEMBL6845042 | 0.75 | ATM (0.32) | — | |
| SCHEMBL4569210 | 0.74 | HSP90AA1 (0.36) | ALOX15TSHRHSP90AA1HSP90AB1RPS6KA3 | |
| SCHEMBL376443 | 0.72 | AXL (0.38) | — | |
| SCHEMBL6842161 | 0.72 | DRD4 (0.43) | TSHR | |
| SCHEMBL6842155 | 0.72 | EPHB3 (0.35) | FABP4 | |
| SCHEMBL21903125 | 0.71 | HDAC8 (0.32) | — | |
| SCHEMBL5495169 | 0.71 | SMPD3 (0.37) | TSHR | |
| SCHEMBL12549813 | 0.71 | HSP90AA1 (0.33) | HSP90AA1HSP90AB1 | |
| SCHEMBL23109050 | 0.70 | EPHB3 (0.39) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2021057882-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | ALOX15 4056/4885TSHR 1608/4885HSP90AA1 1231/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALOX15 3036/4885TSHR 4487/4885HSP90AA1 1164/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALOX15 3032/4885TSHR 4477/4885HSP90AA1 1155/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | ALOX15 423/4885TSHR 2433/4885HSP90AA1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.